Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib
Clinical trial NCT02759016 · COMPLETED
Trial details
- NCT number
- NCT02759016
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-23
- Primary completion
- 2019-06-03
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.